The c -erbB -2 gene is frequently overexpressed in human breast cancers as a result of gene amplification and / or elevated transcription. We therefore examined a possible usage of promoter regions of the c -erbB -2 gene to express a suicide gene preferentially in breast cancer cells. Previous studies did not reveal the minimal promoter region that enabled transcriptional activation specific to breast cancer cells. The present reporter gene assays using deletion mutants of the c -erbB -2 promoter region demonstrated that the 251 -bp ( À 213 / + 38 from the transcriptional start site ), but not the 125 -bp, fragment ( À 87 / + 38 ) could direct transcription of the linked luciferase gene better than the SV40 immediate early promoter in breast cancer cells. In contrast, the 251 -bp fragment -mediated promoter activity in nonbreast cancer cells and in normal fibroblasts was lower than the activity by the SV40 promoter. The 126 -bp fragment ( À 213 / À 87 ) thereby contains a cis -acting element( s ), which is responsible for the preferential transcriptional activity in breast cancer cells. An electrophoretic mobility shift assay suggested that a possible modification of a transcriptional factor was involved in the tumor specificity. Transfection with the plasmid DNA containing the herpes simplex virus thymidine kinase gene linked with the 251 -bp promoter ( p256 -TK ) resulted in increased sensitivity to ganciclovir in breast cancer, but not in nonbreast cancer cells. Administration of ganciclovir into nude mice bearing human breast tumors that were transfected with the p256 -TK DNA suppressed subsequent growth of the transplanted tumors. These results suggest that delivery of a suicide gene linked with the 251 -bp c -erbB -2 promoter can be a feasible therapeutic strategy specific to breast cancer. Cancer Gene Therapy ( 2001 ) 8, 890 -896 
S
uicide gene therapy, gene -directed enzyme prodrug therapy, is one of the approaches to improve the efficiency of cancer chemotherapy. A variety of enzyme / prodrug systems have been examined for its efficacy and feasibility of clinical application. 1 The most common molecular chemotherapy tested is the combination of the herpes simplex virus thymidine kinase (HSV-TK ) gene and a prodrug ganciclovir ( GCV ). 2 Although the bystander effect produced by the system is beneficial to kill tumor cells, 3 restricted expression of the suicide gene in tumor cells is preferable to promote safety and selectivity of the therapy. Targeted gene therapy for cancer can be accomplished at different levels. Controlled gene expression at transcriptional level using tumor-or tissue -specific regulatory sequences has been examined as one of the targeting therapies. 4 Examples of tumor-directed gene regulation include the use of the promoter region of the alpha -fetoprotein gene and that of the carcinoembryonic antigen gene to express a foreign gene in hepatomas and gastrointestinal tumors, respectively. 5, 6 The human c -erbB -2 gene encodes a 185 -kDa transmembrane tyrosine kinase receptor belonging to the epidermal growth factor receptor family. The c-erbB -2 gene is normally expressed at a low level in a variety of human adult epithelial cells; however, it is frequently overexpressed in breast cancer and in other types of tumors. 7, 8 The overexpression of the c -erbB -2 gene in breast cancer is generated by multiple mechanisms including gene amplification and transcription deregulation. 9 A high level of c -erbB -2 expression can predict a worse response to chemotherapy and is correlated with poor prognosis of the patients. 8 Analysis of regulatory sequences of the c -erbB -2 gene revealed that several regions were responsible for transcriptional activation, but a minimal region required for promoter activity was different among the studies. 10 -15 These previous reports agreed with the finding that a fundamental promoter was included within a 700-bp region upstream from the transcriptional initiation site of the c -erbB-2 gene. However, further deletions of this region from the 5 0 -side affected the promoter activity with varying degrees. Moreover, the promoter activity was primarily assayed in breast cancer cells and the activity in nonbreast cancer cells or normal cells has not been well examined.
Previous preclinical and clinical studies of suicide gene therapy for breast cancer cells showed that a c -erbB -2 promoter region could drive the transcriptional activation of the fused suicide gene. 16 -19 However, the promoters used in these studies were either a 530-bp region or a longer genomic fragment and these reports did not extensively characterize the cell type -specific activity. In this study, we examined the activity of various deletion mutants of the c-erbB -2 gene promoter in breast and nonbreast cancer cells, and in normal fibroblasts and identified a minimum promoter region responsible for preferential transcription in breast cancer cells. We also tested the efficacy of the minimum promoter-mediated suicide gene therapy in vitro and in vivo.
MATERIALS AND METHODS

Cells and animals
Human breast cancer cell lines, MCF7 and BT549, were provided by Dr. Toi ( Komagome Hospital, Tokyo, Japan ) and Dr. Hamaoka ( Hokkaido University, Sapporo, Japan ), respectively. Breast cancer cell lines including OCUBM cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. Human melanoma A875 cells, human lung carcinoma QG56 cells, and human fibroblasts, HFF and MRC -5 cells, were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum. BALB / c nu /nu nude mice (6 -to 8 -week -old female ) were purchased from Japan SLC ( Hamamatsu, Japan ).
Northern blot analysis
RNA ( 20 g ) was subjected to electrophoresis on a formaldehyde -agarose gel and transferred to a nylon filter. The filter was hybridized with [ -32 P]dCTP -labeled human c -erbB -2 cDNA 20 in a solution of 50% formamide /5Â SSC / 50 mM NaH 2 PO 4 /2Â Dendhart's solution /0.1% SDS / 0.1 mg / mL salmon sperm DNA at 428C for 12 hours, and then washed with a solution of 0.2Â SSPE /0.1% SDS several times at 508C. The filter was rehybridized with a human glyceraldehyde 3 -phosphate dehydrogenase ( GAPDH ) cDNA 21 as a control.
Dual luciferase assay
A 533-bp genomic DNA fragment of the c -erbB -2 gene was amplified by polymerase chain reaction (PCR) using primers 5 0 -CCCGGGGGTCCTGGAAGCCACAAGGTA-AAC-3 0 (as a 5 0 primer ) and 5 0 -GGGCTCCCCTGGTTT-CTCCGGTCCCAATGG -3 0 (as a 3 0 primer ). Amplification was performed according to the manufacturer's recommendation (Perkin -Elmer Cetus, Norwalk, CT ) and it consisted of 30 cycles under the following condition: 1 minute at 948C for denaturation, 1 minute at 608C for primer annealing, and 1 minute at 728C for primer extension. The sequences of the PCR products were confirmed to be identical to the published sequence. 10 The 533-bp fragment ( p533 ) corresponding to the À 495 / +38 region ( +1 corresponds to the transcriptional start site) was cloned into the pGL2 basic vector (Promega, Madison, WI ) (p533 -luc ) that contained the firefly luciferase gene without any promoter sequences. Several genomic fragments that were deleted from the 5 0 -upstream side were obtained by digestion with restriction enzymes. The p344 -luc, the p251 -luc, and the p125 -luc DNA were generated by digesting the p533 -luc DNA with SmaI and BlnII, SmaI and PstI, SmaI and BssHII, respectively. The transcriptional activity mediated by each genomic fragment was measured with a dual luciferase reporter assay system (Promega ). Plasmid DNA containing respective c -erbB -2 genomic fragments was transfected into target cells with a control vector, the renilla luciferase gene fused with the HSV-TK promoter (pRL -TK ) ( Promega), at a molar ratio of 10:1 with a lipofectin reagent ( Life Technologies, Gaithersburg, MD ). Two days later, cells were lysed and the luciferase activity was measured according to the manufacturer's protocol. The relative firefly luciferase activity of each cell lysate was calculated based on amounts of luminescence produced by the renilla luciferase gene. All of the values were expressed as a mean of three independent experiments.
In vitro sensitivity to GCV
The 251-bp ( À 213 / +38 ) fragment was ligated into the pcDNA3 vector ( Invitrogen, San Diego, CA ) from which the cytomegalovirus (CMV ) promoter was removed ( pro251 ). The HSV-TK gene was cloned into the downstream of the c-erbB -2 ( pro251 -TK ) or the CMV promoter ( CMV-TK ). Cells were transfected with each plasmid DNA, and G418 -resistant cells were selected. These pooled cells were seeded in 96 -well plates at a density of 5Â10 3 cells / well and were cultured with various concentrations of GCV. After 5 -7 days, viable cell numbers in each well were measured with a cell counting kit ( Wako, Osaka, Japan ). The amount of formazan produced in each well was determined from the absorbance at 450 nm. The statistical analysis was performed by one-way analysis of variance (ANOVA ).
Animal study MCF7 cells were transfected with the pro251 or the pro251 -TK DNA, and respective G418 -resistant cells ( 1Â10 7 ) were inoculated subcutaneously into nude mice. From days 10 to 15, GCV ( 30 mg / kg/ d) or phosphate -buffered saline ( PBS ) as a control was intraperitoneally administered. Tumor volumes were calculated according to the formula: tumor volume =0.5ab 2 , where a and b are the larger and the smaller diameters, respectively. The statistical analysis was performed by one -way ANOVA.
Electrophoretic mobility shift assay
Nuclear extracts were prepared from subconfluent cells according to the method of Dignam. 22 The 126-bp fragment
MAEDA, O -WANG, MATSUBARA, ET AL: CYTOTOXICITY BY C -ERBB -2 PROMOTER -DRIVEN HSV -TK ( À 213 / À 87 ) end -labeled with [ -32 P ]ATP was incubated with 6 g of nuclear extracts, 5 g of poly( dI -dC ) ( Pharmacia Biotech, Uppsala, Sweden ) and, in some cases, a 20 -100 M excess of unlabeled DNA fragment as a competitor in 20 L of binding buffer consisting of 10 mM Tris -HCl ( pH 7.5 ), 50 mM NaCl, 0.5 mM DTT, 10% glycerol, 0.5 mM phenylmethylsulfonyl fluoride, and 1 mM EDTA for 30 minutes on ice. The reaction mixtures were then resolved through a 4% polyacrylamide gel in a solution of 67 mM Tris -HCl ( pH 7.5 ), 33 mM sodium acetate, and 10 mM EDTA.
RESULTS
Expression of the c -erbB -2 gene in various cell lines
We examined the expression level of the endogenous c-erbB -2 gene in human breast and nonbreast cancer cell lines, and in normal fibroblasts ( Fig 1 ) . All of the cell lines tested expressed the c-erbB -2 gene, and the level was variable among the cell lines. Southern blot analysis showed that the copy number of the c -erbB -2 gene in OCUBM cells did not increase in spite of their high expression level (data not shown ). Transcriptional activity by c -erbB -2 promoters
We constructed a series of fusion genes consisting of cerbB -2 5 0 flanking sequences linked to the luciferase reporter gene. The structures of chimeric genes are illustrated in Figure 2A . These reporter genes were transfected into breast cancer or other cells, and the respective luciferase activities were standardized by the activity of cotransfected pRL -TK DNA to compensate for the difference of transfection efficiency. We then compared the transcriptional activity of each chimeric gene with that of the SV40 promoter-linked luciferase gene in parallel transfection to give a relative promoter activity. In respective breast cancer cell lines, transfection with the p251 -luc DNA gave the greatest luciferase activity among all of the reporter gene constructs ( Fig 2B ) . The transcriptional activity by the p251 promoter, when tested in OCUBM and MCF7 cells, was much greater than that by SV40 promoter ( P <.01, ANOVA ). Sequential deletion of the p533 DNA from the 5 0 -side in the chimeric reporter gene resulted in increased transcriptional activity, when the deletion reached up to À 251. Transfection with the p125 -luc DNA showed marked decrease in the luciferase activity.
In contrast, the luciferase activity by the p533 -luc DNA in two kinds of human fibroblasts was comparable to the SV40 promoter-mediated activity (Fig 2C ) . The activity by the p251 promoter was lower than that by the SV40 promoter, showing that differential promoter activities between breast cancer cells and normal fibroblasts were greater in that by the p251 promoter than by the p533 promoter. In nonbreast cancer cells, sequential deletion of the p533 DNA from the 5 0 -side in general decreased the promoter activity. In nonbreast cancer cells, the promoter activity by respective DNA fragments was lower than that by the SV40 promoter and the activities mediated by the p533 -, p344 -, or p251 -luc DNA were not markedly different from each other (Fig 2D ) .
Cytotoxicity test in vitro
We examined whether MCF7 or A875 cells transfected with the 251 -bp promoter fused with the HSV-TK gene ( pro256 -TK ) increased their sensitivity to GCV. The CMV-TK or pro251 DNA was also transfected as control. Respective G418 -resistant cells were not different in their proliferation rates in vitro or in their morphology from parental cells. The sensitivity to GCV was significantly increased in MCF7 cells transfected with the pro251 -TK DNA and to a less extent increased in cells transfected with the CMV-TK DNA ( Fig  3A ) . The sensitivity of MCF7 cells transfected with the pro251 DNA cells was not different from that of parent cells ( Fig 3A ) . In breast cancer BT549 cells, the sensitivity was increased when they were transfected with the pro251 -TK or the CMV-TK DNA, but not with the pro251 DNA ( data not shown). However, the increased sensitivity of nonbreast cancer A875 cells transfected with the pro251 -TK DNA was marginal, and the increased level was much lower in A875 transfected with CMV-TK DNA ( Fig 3B ) . The sensitivity of the p251pro DNA -transfected A875 cells remained the same as that of parental cells. 
Cytotoxicity test in vivo
G418 -resistant MCF7 cells transfected with the pro251 -TK DNA (MCF7 /pro251 -TK ) or the pro251 DNA (MCF7/ pro251 ) were inoculated into nude mice. The growth of respective tumors was not different from that of parental MCF7 tumors (data not shown ). From days 10 to 15 after the inoculation, mice were intraperitoneally injected with either GCV or PBS as a control. Administration of GCV resulted in significant suppression of subsequent growth of MCF7/ pro256 -TK tumors, and all of the established tumors were regressed (Fig 4 ) . In contrast, growth of MCF7/ pro251 tumors was temporally retarded by administered GCV, but the tumors regrew thereafter at a similar rate of MCF7 / p256 -TK tumors treated with PBS ( Fig 4 ) .
Detection of DNA -binding activity
Because the promoter activity by the 125 -luc DNA was significantly reduced compared with that by the p251 -luc DNA, we examined whether the À 213/ À 87 fragment could bind any transcription factors. Electrophoretic mobility shift assays detected two slower-and one faster-migrating DNA -protein complexes in all of the six cell lines ( Fig 5A ) . The intensity of the lower band of the slowermigrating complexes was stronger than the upper band of the complexes in breast cancer cells, whereas the intensity of the lower band was weaker in nonbreast cancer cells. All of the DNA -protein interactions in these complexes were inhibited by an excess of unlabeled À 213 / À 87 fragment, but not by an irrelevant DNA fragment ( Fig 5B ) .
DISCUSSION
We showed in this study that the À 213 / À 87 fragment of the c -erbB -2 gene contained the minimal promoter region, which enabled preferential expression of a transgene in breast cancer cells, and that this promoter-mediated expression of HSV-TK gene selectively killed breast cancer cells. Previous studies also reported the proximal regulatory sequences responsible for the expression of the cerbB -2 gene in breast cancer cells. 10 -15 However, these results were inconsistent in defining the promoter region that gave the maximal transcriptional activity and in particular conferred cell type specificity. The discrepant results in the previous reports were in part due to the difference of the cells used. These studies tested the promoter activity of the c -erbB -2 gene in monkey fibrosarcoma cells 10, 14 or in nonbreast cancer cells such as HeLa cells. 11 Even in the studies which tested the promoter activity in human breast cancer cells, the promoter region that gave the maximum activity was either À 712 / À 494, 15 À 213 / + 38, 12 or À 87 / + 38, 13 depending on cell lines used. Although these studies examined a nontumorigenic breast cell line as a control, the transcriptional activity in normal fibroblasts is important from the standpoint of the specificity in suicide gene therapy. In that sense, our present study investigated the promoter activity using breast cancer cells, nonbreast cancer cells, and fibroblasts, and showed the cell type -specific activity of the c-erbB -2 promoter. The luciferase assay showed that the À 213/ + 38 region contained a cis -acting element( s ) for preferential transcriptional activation in breast cancer cells. The p251 DNAmediated promoter activity of the tested cell lines, however, did not correspond to the expression level of c -erbB -2 gene examined with Northern blot analysis. Because the c-erbB -2 gene expression is influenced by various transcriptional regulations, the p251 promoter is responsible for a part of the whole c -erbB-2 gene regulation, excluding the effects of various transcriptional factors acting beyond the p251 fragment.
Several previous preclinical studies showed that a 530-bp or a 4.6 -kb genomic fragment of the c -erbB -2 gene Cancer Gene Therapy, Vol 8, No 11, 2001 activated the expression of a fused prodrug -activating enzyme. 16 -18 These studies, however, did not extensively analyze the specificity of the promoter activity particularly in normal cells. We showed that the p251 promoter had stronger transcriptional activity than the p533 promoter in three breast cancer cells, but had weaker activity in two normal fibroblast cells. From the therapeutic points of view, the 251 promoter is favorable because adverse effects caused by the expression of a suicide gene in normal peritumoral tissues could be minimal. The efficacy of the 251 promoterdriven HSV-TK gene was evidenced by in vitro and in vivo cytotoxic studies.
The À 213 / +38 region contains a TATA box ( À 26/ À 21 ), a CAAT box ( À 74 / À 70 ), and two potential Sp1 -binding sites ( À 192/ À 183 and À 136/ À 127). 10 There are several reports regarding transcriptional factors that bind to this region and are responsible for transcriptional activation in breast cancer cells. 12,23 -25 The OB -1/AP -2 transcriptional activator derived from c -erbB -2 -overexpressing cell lines bound to short nucleotides over the PstI recognition site ( À 213 ).
12, 23 Chen and Gill 24 identified two palindrome sequences in the À 213 / +38 region, which were associated with the up -regulation of the c-erbB -2 gene: one contained the proximal Sp1 -binding site and the other included the BssHII recognition site ( À 87) and the CAAT box. A nuclear protein RBPJ from a c -erbB -2 -overexpressing cell line bound to both of the sequences. 25 The electrophoretic mobility shift assays in the present study demonstrated three major DNA -protein complexes and these nuclear factors in the complex could be OB -1 /AP -2 and /or RBPJ. The previous studies did not characterize the DNA -binding protein with respect to cell type difference; however, the present study showed a differential signal intensity profile between breast cancer cells and other cells. The two slowermigrating complexes can be composed of an identical transcription factor and the difference of migration might be attributable to protein modifications such as phosphorylation. The modifications of transcription factor could contribute to the preferential promoter activity in breast cancer cells.
In this study, we demonstrated the minimum promoter region of the c-erbB -2 gene relatively specific to breast cancer cells and a possible suicide gene therapy using the promoter. Because selective expression of a transgene in breast cancer cells, but not surrounding normal cells, is crucial for safety and efficacy of gene therapy, aligned promoter regions can enhance the therapeutic potency of a breast cancer -specific gene therapy.
